AbbVie (ABBV) Notes Payables (2012 - 2025)

AbbVie (ABBV) has reported Notes Payables for 14 consecutive years, with $2.5 billion the latest figure, recorded in Q4 2025.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $2.5 billion in Q4 2025; TTM through Dec 2025 was $2.5 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $2.5 billion, changed N/A from the prior year.
• Notes Payables was $2.5 billion for Q4 2025 at AbbVie, down from $3.8 billion in the prior quarter.
• Over five years, Notes Payables peaked at $5.6 billion in Q2 2025 and troughed at $1.0 million in Q4 2022.
• A 5-year average of $902.7 million and a median of $14.0 million in 2021 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables plunged 92.86% in 2022 and jumped 53000.0% in 2025, its largest moves.
• Over 5 years, Notes Payables stood at $14.0 million in 2021, then sank by 92.86% to $1.0 million in 2022, then soared by 100.0% to $2.0 million in 2023, then surged by 50.0% to $3.0 million in 2024, then soared by 83200.0% to $2.5 billion in 2025.
• The last three Notes Payables figures came in at $2.5 billion (Q4 2025), $3.8 billion (Q3 2025), and $5.6 billion (Q2 2025), per Business Quant data.